HeartBeam Inc. Pioneers Cable-Free 12-Lead ECG System for At-Home Cardiac Monitoring

HeartBeam Inc. (NASDAQ: BEAT) has developed a pioneering cable-free system capable of synthesizing a 12-lead electrocardiogram (ECG) from 3D, non-coplanar electrical signals in real time. This innovation allows patients to record an ECG in just 30 seconds at home or anywhere symptoms are felt, significantly reducing delays in care. The system, now FDA cleared for arrhythmia assessment, is under additional FDA review for its 12-lead ECG synthesis software for the same indication, marking a significant step forward in cardiac care technology.

The significance of HeartBeam's system lies in its ability to provide synthesized, 12-lead ECG data outside traditional medical settings, eliminating the need for wires, complex setup, or clinical staff. This breakthrough not only enhances patient convenience but also ensures that physicians can quickly assess symptoms, leading to timely and potentially life-saving interventions. With a recent partnership with AccurKardia, HeartBeam's arrhythmia solution is further enhanced by an FDA-cleared automated rhythm interpretation software, underscoring the company's commitment to advancing cardiac care.

HeartBeam's vision to redefine cardiac care through early detection, proactive monitoring, and informed clinical decisions is supported by its robust intellectual property portfolio, including 20 issued patents and additional pending applications. The company is poised for a commercial launch targeting a $500 million concierge serviceable available market (SAM) and a broader multibillion-dollar patient pay market, backed by a high-margin, recurring revenue model. This development represents a transformative shift in how cardiac conditions are detected and monitored, offering a glimpse into the future of personalized and accessible healthcare.